Artesunate inhibits PDE4 leading to intracellular cAMP accumulation, reduced ERK/MAPK signaling, and blockade of influenza A virus vRNP nuclear export.

[1]  P. Hegemann,et al.  Plasticity and therapeutic potential of cAMP and cGMP-specific phosphodiesterases in Toxoplasma gondii , 2022, Computational and structural biotechnology journal.

[2]  I. Barr,et al.  Resurgence of avian influenza virus , 2022, Science.

[3]  Imran Kazmi,et al.  A European pharmacotherapeutic agent roflumilast exploring integrated preclinical and clinical evidence for SARS CoV‐2 mediated inflammation to organ damage , 2022, British journal of clinical pharmacology.

[4]  M. Świerczyńska,et al.  Antiviral drugs for influenza. , 2022, The Medical letter on drugs and therapeutics.

[5]  B. Aderibigbe,et al.  Recent Advances in the Therapeutic Efficacy of Artesunate , 2022, Pharmaceutics.

[6]  L. Hsiao,et al.  PDE4D targeting enhances anti-tumor effects of sorafenib in clear cell renal cell carcinoma and attenuates MAPK/ERK signaling in a CRAF-dependent manner , 2022, Translational oncology.

[7]  M. Rhee,et al.  Anti-Thrombotic Effects of Artesunate through Regulation of cAMP and PI3K/MAPK Pathway on Human Platelets , 2022, International journal of molecular sciences.

[8]  N. Schlegel,et al.  Clinical Implication of Phosphodiesterase-4-Inhibition , 2022, International journal of molecular sciences.

[9]  Yahong Liu,et al.  The Antimalaria Drug Artesunate Inhibits Porcine Reproductive and Respiratory Syndrome Virus Replication by Activating AMPK and Nrf2/HO-1 Signaling Pathways , 2021, Journal of virology.

[10]  J Zhang,et al.  Progress on the study of the anticancer effects of artesunate , 2021, Oncology letters.

[11]  J. Prickaerts,et al.  The Molecular Biology of Phosphodiesterase 4 Enzymes as Pharmacological Targets: An Interplay of Isoforms, Conformational States, and Inhibitors , 2021, Pharmacological Reviews.

[12]  Wei Zheng,et al.  Drug combination therapy for emerging viral diseases , 2021, Drug Discovery Today.

[13]  S. Reid,et al.  Repurposing Quinoline and Artemisinin Antimalarials as Therapeutics for SARS-CoV-2: Rationale and Implications , 2021, ACS pharmacology & translational science.

[14]  Shile Huang,et al.  Artesunate and Dihydroartemisinin Inhibit Rabies Virus Replication , 2021, Virologica Sinica.

[15]  M. Zaccolo,et al.  Subcellular Organization of the cAMP Signaling Pathway , 2020, Pharmacological Reviews.

[16]  H. Hua,et al.  Complex roles of cAMP–PKA–CREB signaling in cancer , 2020, Experimental Hematology & Oncology.

[17]  Xiao-chen Sun,et al.  Peramivir, an Anti-Influenza Virus Drug, Exhibits Potential Anti-Cytokine Storm Effects , 2020, bioRxiv.

[18]  S. Ludwig,et al.  Dissecting the mechanism of signaling-triggered nuclear export of newly synthesized influenza virus ribonucleoprotein complexes , 2020, Proceedings of the National Academy of Sciences.

[19]  G. Baillie,et al.  Phosphodiesterase 4B: Master Regulator of Brain Signaling , 2020, Cells.

[20]  E. Lau,et al.  Avian influenza human infections at the human-animal interface. , 2020, The Journal of infectious diseases.

[21]  R. Lamb,et al.  Repurposing Papaverine as an Antiviral Agent against Influenza Viruses and Paramyxoviruses , 2020, Journal of Virology.

[22]  P. Ferrante,et al.  The Use of Antimalarial Drugs against Viral Infection , 2020, Microorganisms.

[23]  A. Alizadeh,et al.  Rolipram optimizes therapeutic effect of bevacizumab by enhancing proapoptotic, antiproliferative signals in a glioblastoma heterotopic model. , 2019, Life sciences.

[24]  M. Peiris,et al.  Novel Avian Influenza A Virus Infections of Humans. , 2019, Infectious disease clinics of North America.

[25]  A. Argentiero,et al.  Drugs for Influenza Treatment: Is There Significant News? , 2019, Front. Med..

[26]  G. Gao,et al.  Naproxen Exhibits Broad Anti-influenza Virus Activity in Mice by Impeding Viral Nucleoprotein Nuclear Export. , 2019, Cell reports.

[27]  M. Blackman,et al.  Phosphodiesterase beta is the master regulator of cAMP signalling during malaria parasite invasion , 2019, PLoS biology.

[28]  T. Kuwahara,et al.  Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018 , 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[29]  H. D. de Koning,et al.  Cyclic Nucleotide-Specific Phosphodiesterases as Potential Drug Targets for Anti-Leishmania Therapy , 2018, Antimicrobial Agents and Chemotherapy.

[30]  J. Paulson,et al.  Kinetic analysis of the influenza A virus HA/NA balance reveals contribution of NA to virus-receptor binding and NA-dependent rolling on receptor-containing surfaces , 2018, PLoS pathogens.

[31]  P. Österlund,et al.  Highly Pathogenic H5N1 Influenza A Virus Spreads Efficiently in Human Primary Monocyte-Derived Macrophages and Dendritic Cells , 2018, Front. Immunol..

[32]  K. Subbarao,et al.  Influenza , 2017, The Lancet.

[33]  Keith K. Fenrich,et al.  The role of cAMP and its downstream targets in neurite growth in the adult nervous system , 2017, Neuroscience Letters.

[34]  Christin Müller,et al.  The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo. , 2017, Antiviral research.

[35]  M. Pohl,et al.  Late stages of the influenza A virus replication cycle-a tight interplay between virus and host. , 2016, The Journal of general virology.

[36]  E. Gluenz,et al.  cAMP signalling in trypanosomatids: role in pathogenesis and as a drug target , 2015, Trends in parasitology.

[37]  Yu Sun,et al.  Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis , 2015, Journal of receptor and signal transduction research.

[38]  Huanchun Chen,et al.  14-Deoxy-11,12-dehydroandrographolide exerts anti-influenza A virus activity and inhibits replication of H5N1 virus by restraining nuclear export of viral ribonucleoprotein complexes. , 2015, Antiviral research.

[39]  M. Zaccolo,et al.  cAMP signaling in subcellular compartments. , 2014, Pharmacology & therapeutics.

[40]  R. Webster,et al.  Continuing challenges in influenza , 2014, Annals of the New York Academy of Sciences.

[41]  J. Melero,et al.  Roflumilast Inhibits Respiratory Syncytial Virus Infection in Human Differentiated Bronchial Epithelial Cells , 2013, PloS one.

[42]  O. Planz.  Development of cellular signaling pathway inhibitors as new antivirals against influenza. , 2013, Antiviral research.

[43]  M. Peiris,et al.  Reduction of influenza virus-induced lung inflammation and mortality in animals treated with a phosophodisestrase-4 inhibitor and a selective serotonin reuptake inhibitor , 2013, Emerging Microbes & Infections.

[44]  Boyang Liu,et al.  Rolipram promotes remyelination possibly via MEK-ERK signal pathway in cuprizone-induced demyelination mouse , 2012, Experimental Neurology.

[45]  N. Frossard,et al.  Performing Bronchoalveolar Lavage in the Mouse , 2012, Current protocols in mouse biology.

[46]  F. Liu,et al.  Influenza A Virus Induces Interleukin-27 through Cyclooxygenase-2 and Protein Kinase A Signaling* , 2012, The Journal of Biological Chemistry.

[47]  Stephan Ludwig,et al.  Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo. , 2011, Antiviral research.

[48]  S. Pleschka,et al.  Inhibition of influenza virus-induced NF-kappaB and Raf/MEK/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo. , 2011, Antiviral research.

[49]  K. Ikuta,et al.  Highly Pathogenic H5N1 Avian Influenza Virus Induces Extracellular Ca2+ Influx, Leading to Apoptosis in Avian Cells , 2010, Journal of Virology.

[50]  S. Ludwig.  Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. , 2009, The Journal of antimicrobial chemotherapy.

[51]  U. Moens,et al.  Relations between the mitogen-activated protein kinase and the cAMP-dependent protein kinase pathways: comradeship and hostility. , 2008, Cellular signalling.

[52]  R. Hodges,et al.  Role of cAMP inhibition of p44/p42 mitogen-activated protein kinase in potentiation of protein secretion in rat lacrimal gland. , 2007, American journal of physiology. Cell physiology.

[53]  S. Boulo,et al.  Nuclear traffic of influenza virus proteins and ribonucleoprotein complexes. , 2007, Virus research.

[54]  Kam Y. J. Zhang,et al.  Keynote review: phosphodiesterase-4 as a therapeutic target. , 2005, Drug discovery today.

[55]  N. Dumaz,et al.  Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways , 2005, The FEBS journal.

[56]  U. Moens,et al.  What turns CREB on? , 2004, Cellular signalling.

[57]  Thorsten Wolff,et al.  MEK inhibition impairs influenza B virus propagation without emergence of resistant variants , 2004, FEBS letters.

[58]  G. Baillie,et al.  The Unique Amino-terminal Region of the PDE4D5 cAMP Phosphodiesterase Isoform Confers Preferential Interaction with β-Arrestins* , 2003, Journal of Biological Chemistry.

[59]  G. Baillie,et al.  The role of ERK2 docking and phosphorylation of PDE4 cAMP phosphodiesterase isoforms in mediating cross-talk between the cAMP and ERK signalling pathways. , 2003, Biochemical Society transactions.

[60]  P. Palese,et al.  Trafficking of viral genomic RNA into and out of the nucleus: influenza, Thogoto and Borna disease viruses. , 2003, Virus research.

[61]  G. Johnson,et al.  Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases , 2002, Science.

[62]  L. Palmberg,et al.  The tyrosine kinase inhibitor genistein increases basal cAMP and potentiates forskolin-induced cAMP accumulation in A549 human airway epithelial cells , 2002, Molecular and Cellular Biochemistry.

[63]  J. O'Donnell,et al.  Antidepressant-like Profile and Reduced Sensitivity to Rolipram in Mice Deficient in the PDE4D Phosphodiesterase Enzyme , 2002, Neuropsychopharmacology.

[64]  W. Kolch,et al.  Cyclic AMP-Dependent Kinase Regulates Raf-1 Kinase Mainly by Phosphorylation of Serine 259 , 2002, Molecular and Cellular Biology.

[65]  V. Gallo,et al.  cAMP-dependent Protein Kinase Induces cAMP-response Element-binding Protein Phosphorylation via an Intracellular Calcium Release/ERK-dependent Pathway in Striatal Neurons* , 2001, The Journal of Biological Chemistry.

[66]  Thorsten Wolff,et al.  Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade , 2001, Nature Cell Biology.

[67]  H. Magnussen,et al.  Cyclic nucleotide phosphodiesterase in human bronchial epithelial cells: characterization of isoenzymes and functional effects of PDE inhibitors. , 1998, Pulmonary pharmacology & therapeutics.

[68]  T. Greten,et al.  Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV‐1 replication , 1995, AIDS.

[69]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .

[70]  Bhupal Singh.  Influenza , 1916, Nature Reviews Disease Primers.

[71]  D. Spina.  Phosphodiesterase-4 Inhibitors in the Treatment of Inflammatory Lung Disease , 2012, Drugs.

[72]  X. Wang,et al.  Negative Feedback Regulation of Raf/MEK/ERK Cascade After Sublethal Cerebral Ischemia in the Rat Hippocampus , 2010, Neurochemical Research.